# US 2016/0256405 A1 · Stabilized compositions containing alkaline labile drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256405 A1
- Document ID: US20160256405A1
- Status: Published application
- Kind: A1
- Application number: 15/159,285
- Filed: 2016-05-19
- Published: 2016-09-08
- Earliest claimed: 2006-03-24
- Assignees: Auxilium US Holdings, LLC
- Applicants: Auxilium US Holdings, LLC.
- Inventors: Michael M. CROWLEY; Justin M. KEEN; John J. KOLENG; Feng ZHANG
- Web page: https://patentgrep.com/patent/US20160256405A1

## CPC

- A61K 9/70: Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/7023: {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}
- A61K 9/703: {characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches}
- A61K 9/7084: {Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches}
- A61K 9/7092: {Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs}
- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61K 31/568: substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61L 15/44: Medicaments
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 5/24: of the sex hormones
- A61K 9/7069: {obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide}
- A61L 2300/602: Type of release, e.g. controlled, sustained, slow
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A stabilized bioadhesive composition containing an alkaline labile drug and a method for its preparation are provided. In one aspect, the composition is a hot-melt extruded (HME) composition comprising a preformed excipient mixture comprising an acidic component and an alkaline thermoplastic matrix-forming material, e.g. polymer. The excipient mixture is formed before blending with an alkaline labile drug. The blend is then hot-melt extruded to form the HME composition. By so doing, the acidic component is able to neutralize or render moderately acidic the excipient mixture. This particular process has been shown to substantially reduce the degradation of an alkaline labile drug during hot-melt extrusion. The excipient mixture softens or melts during hot-melt extrusion. It can dissolve or not dissolve drug-containing particles during extrusion. Various functional excipients can be included in the carrier system to improve process performance and/or improve the chemical or physical properties of the HME composition.

## Claims

### Claim 1

A stabilized hot-melt extruded pharmaceutical composition comprising:
a hot-melt extrusion of
(i) a non-alkaline thermoplastic bioadhesive matrix comprising a preformed excipient mixture comprising an alkaline thermoplastic bioadhesive polymer and an acidic component; mixed with
(ii) an alkaline labile drug and optionally one or more other components;
wherein the pharmaceutical composition comprises the matrix in an amount from 50-99.999 wt % and the drug in an amount from 0.001-50 wt. %.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the excipient mixture further comprises a hydrophilic polymer.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition comprises two or more thermoplastic and water swellable, water soluble, or water erodible polymers.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the alkaline thermoplastic bioadhesive polymer is PEO.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the PEO is selected from the group consisting of PEO grade 1, PEO grade 2 and PEO grade 3, wherein PEO Grade 1 is polyethylene oxide with a solution viscosity in the range of 12-8800 mPa·s at 25° C. in a 5% solution or with an approximate molecular weight range from 100,000-600,000; PEO Grade 2 is polyethylene oxide with a solution viscosity in the range of 8800 mPa·S at 25° C. in a 5% solution to 4000 mPa·s at 25° C. in a 2% solution or with an approximate molecular weight range from 900,000-2,000,000; and PEO Grade 3 is polyethylene oxide with a solution viscosity in the range of 1650-15,000 mPa·s at 25° C. in a 1% solution or with an approximate molecular weight range from 4,000,000-8,000,000.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the acidic component is selected from the group consisting of a polymeric organic acid, a non-polymeric organic acid, an inorganic acid, an acidic polymer, and a combination thereof.

### Claim 7 (depends on 1)

The composition of claim 1 further comprising an opaquant.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the alkaline labile drug is selected from the group consisting of testosterone, oxybutynin, morphine, fentanyl, aspirin, lansoprazole, omeprazole, pantoprazole, rabeprazole and naltrexone.

### Claim 9 (depends on 1)

A hot-melt extruded composition comprising the composition of claim 1 and a second composition, wherein the second composition comprises at least one hydrophobic polymer.

### Claim 10 (depends on 9)

The hot-melt extruded composition of claim 9, wherein the hot-melt extruded composition is an immediate release, rapid release, or delayed release therapeutic composition.

### Claim 11 (depends on 9)

The hot-melt extruded composition of claim 9, wherein the hot-melt extruded composition is a controlled, sustained, slow, extended, or targeted release therapeutic composition.

### Claim 12 (depends on 9)

The hot-melt extruded composition of claim 9, wherein the hot-melt extruded composition is a dosage form adapted for transdermal, transmucosal, rectal, pulmonary, nasal, vaginal, ocular, or otic drug delivery, or as an implantable drug delivery device.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the alkaline labile drug is fentanyl.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the alkaline labile drug is testosterone.
